Clarivate Plc
NYSE:CLVTInformation Technology Services
-$0.10 today
- Market cap
- $1.38B
- Beta
- 1.37
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$0.21
Volume 3.95M
Average 5.22M
CLVT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Clarivate PlcNYSE: CLVT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CLVT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for CLVT, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥290.87M CNY | +35.4% | -6.1% | 2.8% | |
| LTM Apr 2026 | $229.09M USD | +1.2% | +2.8% | 91.5% | |
| LTM Mar 2026 | $71.71M USD | -6.4% | -20.7% | 5.5% | |
| LTM Mar 2026 | $39.77M USD | -41.8% | -34.6% | 1.4% | |
| LTM Mar 2026 | $18.12M USD | +30.5% | +25.9% | 14.2% | |
| LTM Jun 2026 | $1M USD | +11.1% | — | 0.3% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Feb 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CLVT) | — | +6.2% | -6.1% | 1.4% | |
Competitors are the stored peer set for CLVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.88B | 2.66B | 2.63B | 2.56B | 2.46B |
| Cost of Revenue | 626.1M | 954M | 906.4M | 869.2M | 833.6M |
| Gross Profit | 1.25B | 1.71B | 1.72B | 1.69B | 1.62B |
| Gross Margin | 66.6% | 64.1% | 65.5% | 66.0% | 66.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 643M | 729.9M | 739.7M | 727.6M | 708.6M |
| Operating Expenses | 1.34B | 5.63B | 2.46B | 1.96B | 1.55B |
| Depreciation & Amortization | 537.8M | 710.5M | 708.3M | 727M | 757.2M |
| EBITDA | 532.16M | (3.01B) | (10.5M) | 456.6M | 828.7M |
| EBITDA Margin | 28.4% | -113.1% | -0.4% | 17.9% | 33.8% |
| Operating Income | (87M) | (3.93B) | (734.7M) | (275.6M) | 71.5M |
| Operating Margin | -4.6% | -147.6% | -27.9% | -10.8% | 2.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 252.5M | 270.3M | 293.7M | 283.4M | 265.4M |
| Other Income / Expenses | (171.2M) | (63.5M) | (277.8M) | (278.2M) | (265.4M) |
| Income Before Tax | (258.2M) | (3.99B) | (1.01B) | (553.8M) | (193.9M) |
| Pre-Tax Margin | -13.8% | -150.0% | -38.5% | -21.7% | -7.9% |
| Income Tax Expense | 12.3M | (28.9M) | (101.3M) | 82.9M | 7.2M |
| Net Income | (270.5M) | (3.96B) | (911.2M) | (636.7M) | (201.1M) |
| Net Margin | -14.4% | -148.9% | -34.7% | -24.9% | -8.2% |
| EPS (Basic) | (0.62) | (6.26) | (1.47) | (0.96) | (0.30) |
| EPS (Diluted) | (0.61) | (6.24) | (1.47) | (0.96) | (0.30) |
| Weighted Avg Shares | 630.98M | 676.1M | 671.6M | 693.6M | 673.3M |
| Weighted Avg Shares (Diluted) | 640.77M | 678.6M | 671.6M | 693.6M | 673.3M |
Clarivate Plc
NYSE:CLVT
Intrinsic Alpha fair value
Locked
Current Price
$2.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.